JO
ACRS icon

John Overdeck’s Aclaris Therapeutics ACRS Stock Holding History

John Overdeck’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$704K Sell
133,068
-262,569
-66% -$1.17M ﹤0.01% 3891
2026
Q1 		$1.48M Sell
395,637
-178,576
-31% -$603K ﹤0.01% 2986
2025
Q4 		$1.73M Buy
574,213
+206,106
+56% +$521K ﹤0.01% 2540
2025
Q3 		$699K Sell
368,107
-381,553
-51% -$665K ﹤0.01% 2805
2025
Q2 		$1.06M Sell
749,660
-70,604
-9% -$95.5K ﹤0.01% 2206
2025
Q1 		$1.26M Sell
820,264
-19,006
-2% -$40.5K ﹤0.01% 2047
2024
Q4 		$2.08M Sell
839,270
-68,646
-8% -$171K ﹤0.01% 1678
2024
Q3 		$1.04M Sell
907,916
-205,156
-18% -$252K ﹤0.01% 2095
2024
Q2 		$1.22M Sell
1,113,072
-216,544
-16% -$254K ﹤0.01% 1881
2024
Q1 		$1.65M Sell
1,329,616
-133,845
-9% -$160K ﹤0.01% 1618
2023
Q4 		$1.54M Buy
1,463,461
+1,437,561
+5,550% +$4.39M ﹤0.01% 1796
2023
Q3 		$177K Buy
+25,900
New +$221K ﹤0.01% 2660
2023
Q2 		– Sell
-84,442
Closed -$683K – 2974
2023
Q1 		$683K Buy
84,442
+73,742
+689% +$936K ﹤0.01% 2060
2022
Q4 		$169K Buy
+10,700
New +$172K ﹤0.01% 2425
2022
Q1 		– Sell
-13,044
Closed -$190K – 2561
2021
Q4 		$190K Sell
13,044
-96,784
-88% -$1.47M ﹤0.01% 3936
2021
Q3 		$1.98M Sell
109,828
-265,474
-71% -$4.26M ﹤0.01% 2004
2021
Q2 		$6.59M Buy
375,302
+201,226
+116% +$4.57M 0.01% 1026
2021
Q1 		$4.39M Buy
174,076
+87,984
+102% +$1.72M 0.01% 1140
2020
Q4 		$557K Buy
+86,092
New +$363K ﹤0.01% 2435
2019
Q3 		– Sell
-71,581
Closed -$157K – 3397
2019
Q2 		$157K Sell
71,581
-92,116
-56% -$502K ﹤0.01% 3133
2019
Q1 		$981K Buy
163,697
+58,368
+55% +$387K ﹤0.01% 1842
2018
Q4 		$778K Buy
+105,329
New +$1.09M ﹤0.01% 1815

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

John Overdeck's ACRS Position: Q2 2026 in Review

John Overdeck reduced its Aclaris Therapeutics (ACRS) stake by 66% in Q2 2026, selling an estimated $1.17M and leaving 133,068 shares worth $704K. The position accounts for ﹤0.01% of the portfolio, ranked #3891.

John Overdeck first reported a position in ACRS in Q4 2018 and has held it in 22 quarters since. The position peaked at $6.59M in Q2 2021. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • John Overdeck held 133,068 shares of Aclaris Therapeutics worth $704K as of Q2 2026.
  • John Overdeck sold 262,569 Aclaris Therapeutics shares in Q2 2026, an estimated $1.17M.
  • Aclaris Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3891 holding.
  • John Overdeck first reported a position in Aclaris Therapeutics in Q4 2018 and has held it in 22 quarters since.
  • John Overdeck's Aclaris Therapeutics position peaked at $6.59M in Q2 2021.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.